ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ICUI vs PLSE // EV/EBITDA & P/E VALUATION

ICU Medical Inc. (NASDAQ) VS. Pulse Biosciences Inc (NASDAQ) • 15-METRIC TALLY: ICUI 7 — PLSE 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ICUI VS. PLSE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ICUI PLSE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 36.80% -30.00% +66.80 ICUI /gross-margins <GO>
Return on Invested Capital (ROIC) 1.00% -30.70% +31.70 ICUI /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 46.6x — — TIE /valuation <GO>
Free Cash Flow Yield 2.18% -1.38% +3.56 ICUI /fcf-yield <GO>
Operating Margin 1.90% -60.00% +61.90 ICUI /operating-margins <GO>
Net Profit Margin 0.00% -60.00% +60.00 ICUI /net-margins <GO>
Revenue Growth (YoY) -6.30% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 8/9 2/9 +6.00 ICUI /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 56.5 59.7 -3.20 PLSE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $4.22B $3.96B $260.5M ICUI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ICUI REV PLSE REV ICUI GROSS % PLSE GROSS % ICUI FCF PLSE FCF
FY 2025 $2.23B $350.0K 36.8% -50.0% $91.8M -$54.4M
FY 2024 $2.38B $0 34.6% — $124.7M -$36.5M
FY 2023 $2.26B $0 — — $166.2M -$33.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ICUI // BETA —
PLSE // BETA —